secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0000078003-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer FY2022 revenue record $100.3B, adj. EPS $6.58; FY2023 guidance $67-71B rev, adj. EPS $3.25-3.45
--------------------------------------------------------------------------------

- Full-year 2022 revenues $100.3B (record), up 23% YoY; reported EPS $5.47, adjusted EPS $6.58.
- Q4 revenues $24.3B, reported EPS $0.87, adjusted EPS $1.14.
- FY2023 revenue guidance $67-71B (down ~31%), adjusted EPS $3.25-3.45 (down ~49% operational).
- Excluding COVID products, Pfizer expects 7-9% operational revenue growth in 2023.
- Completed ~$26B in acquisitions in 2022 (Biohaven, Arena, GBT); $9B dividends, $2B share repurchases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/pfe-20230131.htm
  HTML page:      https://secwatch.observer/filing/0000078003-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer